Detalles de la búsqueda
1.
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Hepatology
; 76(4): 1000-1012, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35313048
2.
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study.
Liver Int
; 43(3): 695-707, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36577703
3.
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.
Liver Int
; 42(11): 2538-2547, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35986902
4.
Trends of female authorship in head and neck surgery publications over the last decade.
Head Neck
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752400
5.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Hepatol Int
; 17(4): 904-914, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37005953
6.
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
Hepatol Commun
; 6(7): 1776-1785, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35481940
7.
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study.
J Immunother Cancer
; 10(6)2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35710293
8.
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma.
Ther Adv Med Oncol
; 13: 17588359211010937, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33995594
9.
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma.
Liver Cancer
; 10(6): 583-592, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34950181
10.
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice.
Eur J Cancer
; 157: 140-152, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34508996
11.
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma.
Cancers (Basel)
; 14(1)2021 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008350
12.
Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study.
J Clin Med
; 9(9)2020 Aug 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32824968
13.
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
J Immunother Cancer
; 8(2)2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32868393
14.
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade.
Cancers (Basel)
; 12(7)2020 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32664319
15.
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy.
J Immunother Cancer
; 8(2)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33028690
Resultados
1 -
15
de 15
1
Próxima >
>>